Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables - Accured: 2024-2025

Historic Receivables - Accured for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to $3.3 million.

  • Kura Oncology's Receivables - Accured rose 73.68% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 73.68%. This contributed to the annual value of $3.3 million for FY2024, which is N/A change from last year.
  • Kura Oncology's Receivables - Accured amounted to $3.3 million in Q3 2025, which was down 8.33% from $3.6 million recorded in Q2 2025.
  • Kura Oncology's 5-year Receivables - Accured high stood at $3.9 million for Q1 2025, and its period low was $1.5 million during Q1 2024.
  • For the 2-year period, Kura Oncology's Receivables - Accured averaged around $2.8 million, with its median value being $3.3 million (2025).
  • Data for Kura Oncology's Receivables - Accured shows a peak YoY spiked of 160.00% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows Kura Oncology's Receivables - Accured stood at $3.3 million in 2024, then spiked by 73.68% to $3.3 million in 2025.
  • Its Receivables - Accured was $3.3 million in Q3 2025, compared to $3.6 million in Q2 2025 and $3.9 million in Q1 2025.